Sugi Predict

Sugi Predict / Targets / KMT5C

KMT5C

Histone-lysine N-methyltransferase KMT5C · Q86Y97 · KMT5C on Sugi Atlas →

2,788 patent compounds predicted against KMT5C, 2,221 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL1613404 SCHEMBL1613404 0.81 2/20
SCHEMBL4963680 SCHEMBL4963680 0.80 2/20
SCHEMBL1147527 SCHEMBL1147527 0.78 2/20
SCHEMBL3706336 SCHEMBL3706336 0.78 2/20
SCHEMBL3708467 SCHEMBL3708467 0.78 2/20
SCHEMBL3711288 SCHEMBL3711288 0.78 2/20
SCHEMBL4811736 SCHEMBL4811736 0.78 2/20
SCHEMBL6861746 SCHEMBL6861746 0.78 2/20
SCHEMBL6861753 SCHEMBL6861753 0.78 2/20
SCHEMBL1147688 SCHEMBL1147688 0.76 2/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL1876988) 0.76 2/20
SCHEMBL6865829 SCHEMBL6865829 0.76 2/20
SCHEMBL6865834 SCHEMBL6865834 0.76 2/20
SCHEMBL1147609 SCHEMBL1147609 0.74 2/20
SCHEMBL4810793 SCHEMBL4810793 0.71 2/20
SCHEMBL1147647 SCHEMBL1147647 0.71 2/20
SCHEMBL1550555 SCHEMBL1550555 0.71 2/20
SCHEMBL3711092 SCHEMBL3711092 0.70 2/20
SCHEMBL6866156 SCHEMBL6866156 0.70 2/20
SCHEMBL6866164 SCHEMBL6866164 0.70 2/20

Clinical trials — most relevant to KMT5C by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis PHASE1/PHASE2RECRUITING
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia PHASE2RECRUITING
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS PHASE2COMPLETED
Phase Ⅰ/Ⅱ Study of SHR2554 in Combination With SHR1701 in Patients With Advanced Solid Tumors and B-cell Lymphomas PHASE1/PHASE2UNKNOWN
An Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With Ustekinumab PHASE1/PHASE2RECRUITING
Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma PHASE1/PHASE2COMPLETED
A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors PHASE1/PHASE2RECRUITING
IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome PHASE2ACTIVE_NOT_RECRUITING
A Study of JNJ-75276617 in Combination With Conventional Chemotherapy for Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias PHASE1WITHDRAWN
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome PHASE1COMPLETED
Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma PHASE1ACTIVE_NOT_RECRUITING
5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors PHASE1RECRUITING
Safety, Tolerability and Pharmacokinetics of Benfo-Oxythiamine (B-OT) in Healthy Volunteers PHASE1COMPLETED
Azacitidine in Combination With Mitoxantrone, Etoposide Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia PHASE1COMPLETED
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients nanRECRUITING
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia nanUNKNOWN
Exploiting Epigenome Editing in Kabuki Syndrome: a New Route Towards Gene Therapy for Rare Genetic Disorders nanCOMPLETED
Mechanisms of Immune Deficiency nanUNKNOWN
Studying Genes in Samples From Younger Patients With Relapsed Acute Lymphoblastic Leukemia nanCOMPLETED
Epigenetic Evaluation of HAT/HDAC Activity in PBMC From Patients With Clinically Isolated Syndrome nanUNKNOWN
The Crosstalk Between the Epigenome and Mitochondria in SCI nanNOT_YET_RECRUITING
Diagnosis of RSTS: Identification of the Acetylation Profiles as Epigenetic Markers for Assessing Causality of CREBBP and EP300 Variants. nanUNKNOWN
Target of Suv420h1/2 in Hepatocytes nanRECRUITING
Liquid Biopsy in Germ Cell Tumors nanNOT_YET_RECRUITING
The Association of G9a Protein and Clinical Outcome of Patients With Vulvar Cancer nanUNKNOWN
The Molecular Pathogenesis Study of Cataract nanUNKNOWN
Clinical, Radiological, Histologic and Molecular Features of a Cohort of Melanocytic Tumors of the Central Nervous System nanUNKNOWN
CMOP Regimen and Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma nanUNKNOWN
Impact of a Monoamine Oxidase Inhibitor on the Phenotype of Blood Mononucleated Cells in Patients With COVID-19 nanCOMPLETED
Study of Tazemetostat in Adults With Follicular Lymphoma Previously Treated With at Least Two Therapies nanWITHDRAWN

Related proteins — ESM-2 sequence neighbours (a KMT5C binder may also engage these)

ProteinNameSimilarity
P0C2N6 — 0.995 P0C2N6 →
Q6Q783 — 0.994 Q6Q783 →
MAP3K10 Mitogen-activated protein kinase kinase kinase 10 0.983 landscape →
Q8BQU6 — 0.982 Q8BQU6 →
Q76KP1 — 0.981 Q76KP1 →
D3ZG83 — 0.981 D3ZG83 →
A2A699 — 0.980 A2A699 →
LMTK3 Serine/threonine-protein kinase LMTK3 0.980 landscape →
A2AEV7 — 0.980 A2AEV7 →
Q7TN12 — 0.980 Q7TN12 →
Q29RK8 — 0.980 Q29RK8 →
TESK1 Dual specificity testis-specific protein kinase 1 0.980 landscape →
Q2M3V2 — 0.979 Q2M3V2 →
A8MVW0 — 0.979 A8MVW0 →
Q566C8 — 0.979 Q566C8 →
O43900 — 0.979 O43900 →
O43918 — 0.979 O43918 →
O94761 — 0.979 O94761 →
Q96FS4 — 0.979 Q96FS4 →
Q66HA1 — 0.978 Q66HA1 →
E1BEA8 — 0.978 E1BEA8 →
Q8BY98 — 0.978 Q8BY98 →
Q80XI6 — 0.978 Q80XI6 →
Q9Z0E3 — 0.978 Q9Z0E3 →
Q8BLS7 — 0.978 Q8BLS7 →
Q5T442 — 0.978 Q5T442 →
Q9H6W3 — 0.978 Q9H6W3 →
A6NIN4 — 0.978 A6NIN4 →
Q9Z188 — 0.978 Q9Z188 →
Q90ZZ6 — 0.977 Q90ZZ6 →